Press Release Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World’s First Approved 4-1BB-Targeting Therapy 4 hours ago
Press Release Priority Review Granted to PD-L1/4-1BB Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in EP-NEC Jul 10